凯莱英（06821）今日盘中大涨5.18%，引起了市场的广泛关注。
消息面上，医药外包（CXO）概念股今日开盘普遍上涨。万联证券指出，2025年全球及中国医疗健康领域一级市场投融资回暖，叠加中国创新药BD出海授权交易额、首付款均创历史新高，为药企研发及运营补充了关键资金。在此背景下，全球及中国CXO市场预计将在2026年迎来稳定增长，行业景气度随下游需求复苏而修复。同时，修订后美国《生物安全法案》对特定企业的明确排除及缓冲期设计，有望大幅缓释地缘政治风险，推动国内CXO行业在全球产业链中的地位进一步巩固与扩张。该机构对CXO行业维持“强大于市”评级，市场情绪因此受到提振。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.